drugset / Trial / NCT00338000

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

NCT00338000

Phase 4 Completed 292 enrolled Janssen Pharmaceutica N.V., Belgium
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the effectiveness, safety and clinical outcome of Epoetin alfa with dosing regime in accordance with Summary of Product Characteristics in the treatment of anemia in predialysis.

Timeline

Start
2001-06
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 50 iu/kg Subcutaneous